Metagenomi Therapeutics, Inc.

MGX

CIK 0001785279 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$4M
↓-59.3% -$6Mvs FY2024 (Q4)
Gross Profit
$4M
↓-59.3% -$6Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
17/100
  • Profitability
    0ROIC -38.6% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 7.22 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.09x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -59.3% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -263.8% · trend -215.2pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$574K
investment in PP&E
Stock-based comp (TTM)
$12M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$221M
everything owned
Total liabilities
$63M
everything owed
Stockholders' equity
$159M
shareholder claim

Recent performance · 12 quarters

Revenue↓-59.3% -$6M
$4M
Net Income↓-8.6% -$2M
$-20M
Free Cash Flow↑+74.6% +$249K
$-85K
Operating Margin↓-69.4pts
-263.8%

Drill down